Depending upon how much weight you lose some bone loss might be sensible.
chatGPT(6AstraMaxPaid):
The paper provides a useful account of why weight loss can harm bone, but its novelty is mainly an updated synthesis, and several statements need more careful interpretation. It also contains a substantive problem in its description of a cited treatment trial.
The paper is Why Do We Lose Bone During Weight Loss: Can It Be Prevented?, by Sue A. Shapses and Brandon D. McGuire, published in Current Osteoporosis Reports in September 2026. It is a narrative review, with no new experimental dataset.
Summary. The authors argue that weight loss can shift bone remodelling towards net loss through several interacting mechanisms. Reduced mechanical loading explains part of this response, but nutritional and hormonal changes also matter.
The main findings are:
- Moderate weight loss can reduce hip bone density. The review reports that losing approximately 5-10% of body weight is associated with around 1-2.5% loss of total hip bone mineral density, or BMD. Effects vary by population, skeletal site and intervention.
- Older adults and postmenopausal women are particularly vulnerable. Lower starting body weight and loss of muscle may increase susceptibility. Some younger adults with obesity show little measurable bone loss, whereas calorie restriction in adults without obesity can reduce BMD.
- Greater or more severe weight loss can produce larger skeletal effects. In the cited TEMPO trial, severe restriction produced approximately 15 kg weight loss versus 8 kg with moderate restriction, accompanied by about 2.5 times as much hip BMD loss.
- Weight regain does not reliably restore lost bone. Studies in older adults suggest that skeletal losses can persist after dieting ends, raising concerns about repeated weight cycling.
- Bone quality matters alongside density. Changes in cortical thickness, internal architecture and bone geometry can influence strength even when changes in conventional BMD appear modest.
The proposed mechanisms have different levels of support:
| Mechanism | Proposed contribution | Important qualification |
|---|---|---|
| Reduced mechanical loading | Lower body weight and muscle forces reduce the stimulus for bone formation | Does not fully explain losses at non-weight-bearing sites or persistence after weight regain |
| Reduced calcium availability | Lower dietary intake and reduced intestinal absorption can produce negative calcium balance | Absorption can decline even when blood vitamin D levels rise |
| Hormonal changes | Changes in oestrogen, parathyroid hormone and sclerostin can favour resorption or suppress formation | Responses vary; for example, IGF-1 does not consistently decline during human weight loss |
| Loss of muscle | Reduces skeletal loading and may increase vulnerability to falls | Muscle function and strength need consideration alongside lean mass |
| Gut microbiome changes | Altered microbial metabolites, inflammation and permeability may affect bone | Direct causal evidence in humans remains limited |
For prevention, the authors emphasise adequate calcium and protein intake, sufficient vitamin D, and exercise. These measures can attenuate bone loss, but complete prevention is not established. Higher vitamin D doses did not consistently improve skeletal outcomes in the trials discussed. Weighted vests also failed to prevent hip bone loss in a large trial.
GLP-1-based treatments receive particular attention. The review reasonably observes that bone loss during semaglutide treatment does not, by itself, establish a direct adverse action of the drug on bone: the accompanying weight loss could mediate the effect. Evidence on fractures specifically in people treated for obesity remains incomplete.
Novelty. The paper’s contribution is primarily to bring established skeletal concerns into the context of increasingly effective obesity treatments.
Its more contemporary elements are:
- Integrating evidence on incretin therapies, bariatric surgery and severe dietary restriction.
- Incorporating recent trials of exercise, weighted vests and protein supplementation.
- Discussing microbiome changes, circadian biology and time-restricted eating as possible intervention targets.
However, the principal mechanisms and the observation that dieting can reduce BMD have been recognised for decades. The paper also cites other recent reviews covering much of this territory. It offers an accessible update, rather than establishing a new mechanism or a proven prevention strategy.
Critique. Its strongest feature is its recognition that skeletal responses depend on several interacting factors. It also acknowledges meaningful differences between animal and human findings, including inconsistent responses of IGF-1 and bone marrow fat. The main weaknesses are the following.
-
The review does not systematically grade the evidence.
There is no reported reproducible search strategy, formal study-selection process or structured assessment of bias. Human randomised trials, observational associations, animal experiments and preliminary findings therefore sit alongside one another without a consistent indication of evidential strength. This makes some proposed mechanisms appear more settled than they are.
-
One treatment trial is described misleadingly.
On page 6, the review says that raloxifene and oestrogen showed no apparent skeletal benefit during exercise-induced weight loss. However, the cited Gozansky trial reported average BMD changes across measured sites of approximately -1.5% with placebo, -0.5% with raloxifene and +1.1% with hormone therapy in the weight-loss groups.
The trial found no significant interaction between weight loss and drug treatment. That means it did not demonstrate that treatment specifically changed the effect of weight loss; it does not mean the treatments provided no skeletal benefit. The review should distinguish these conclusions. Original trial.
-
The fracture-risk figures need better context.
The review mentions a 3.5-fold increase in hip-fracture risk associated with a femoral BMD difference of 0.12 grams per square centimetre. The cited meta-analysis explains that this represents approximately one standard deviation of BMD, whereas the dietary interventions produced average hip BMD losses of only 0.010-0.015 grams per square centimetre. The 3.5-fold figure therefore cannot be read as the expected consequence of a typical dieting episode. Cited meta-analysis.
Similarly, the Look AHEAD result was a 39% higher hazard of the specified frailty-fracture outcome in the intervention group, not evidence for a biological threshold at 7% weight loss. Seven per cent was the intervention target. Total fractures and hip fractures did not differ significantly between groups. Look AHEAD trial.
-
Weight-loss magnitude, speed and method remain difficult to separate.
Severe dietary restriction changes several things simultaneously: energy availability, weight-loss rate, total weight lost and potentially nutrient intake. Statistical adjustment for body weight does not fully isolate the effect of speed. Likewise, a semaglutide-versus-placebo trial estimates the overall treatment effect, but cannot separate direct drug effects from effects mediated by weight loss without additional comparisons.
-
The fasting and microbiome arguments are preliminary.
Preserved BMD in a time-restricted eating group that did not lose significant weight provides little evidence that meal timing protects bone during equivalent weight loss. The authors’ additional findings are explicitly preliminary. Demonstrating protection would require comparable weight loss, nutrition and activity between groups, with stronger evidence that microbiome changes actually mediate the skeletal response.
-
Preserving BMD is not the same as demonstrating fracture prevention.
Many interventions are supported by relatively short studies of BMD or turnover markers. Fractures also depend on falls, muscle function and bone architecture. The review consequently provides stronger support for measures that may reduce skeletal deterioration than for any particular strategy proven to prevent fractures during weight loss.
The most informative next studies would compare interventions producing similar weight loss, standardise calcium and protein intake, and assess bone structure, muscle function and falls alongside BMD. Longer follow-up would establish whether apparent skeletal protection translates into fewer fractures.